The medicinal product Pegasys® 180µg, solution for injection, will have limited availability in Belgium until June 2025. Experts of the task force Unavailability recommend the following.

The European Commission is considering allowing the use of electronic instructions for use for all devices for professional use. The Commission is therefore launching a survey for healthcare professionals.

The Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA), having analysed recent reports on diabetic ketoacidosis associated with Senvelgo use, now issues recommendations.

During its July 2024 meeting, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency issued new recommendations for GLP-1 receptor agonists and agreed a direct healthcare professional communication for glatiramer acetate containing products.

New measures published in the European Union’s Official Journal come into effect to improve the availability of in vitro diagnostics, for patients and healthcare providers.

During its June 2024 meeting, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency started a review of the painkiller metamizole and identified a risk of secondary malignancies of T-cell origin with CAR T- cell medicines.

The EMA's Committee for Veterinary Medicinal Products (CVMP) recommends suspending the marketing authorisation for Kexxtone 32.4 g continuous-release intraruminal device for cattle (EU/2/12/145/001-003) and recalling batches from the market.

The European Medicines Regulatory Network (EMRN), of which the FAMHP is part, has been designated as WHO Listed Authority by the World Health Organisation.